Retatrutide 30mg
$117.99
- Retatrutide peptide is a triple agonist (GLP-1R + GIPR + GCGR) — the only compound in development that targets all three receptors simultaneously
- Phase 2 NEJM trial: up to 24.2% body weight reduction at 48 weeks; newer 68-week data shows 28.7% at the highest dose
- Outperforms both semaglutide (~15%) and tirzepatide (~20%) on average weight loss in trials
- The glucagon receptor component adds direct fat-burning and energy expenditure effects not found in other GLP-1 drugs
- Side effects are primarily GI and dose-dependent — similar profile to other GLP-1 class drugs